↓
 

Hepatitis C Blog

Hepatitis C Blog
  • Home
  • Eblast SignUp

Monthly Archives: March 2015

Post navigation

← Older posts

Pakistan: Thousands of Pakistan made anti Hepatitis C injections expire

Hepatitis C Blog Posted on March 31, 2015 by HCV AdvocateDecember 13, 2015

Islamabad- About 10000 injections developed by Punjab University (PU) for treatment of Hepatitis-C have gone redundant, due to negligence of provincial and federal governments.

The government has shifted all the burden of this scam to the shoulders of former PPP led government. PU medical experts had developed 100000 injections for cure of Hepatitis-C at the cost of Rs 7 million, but these have gone time barred while lying in stores, due to non-granting of permission by ministry of health and regulation for conducting laboratory test.

PU Molecular Biology department worked out plan to develop cheap Interferon injection for treatment of Hepatitis C and funds were also provided to the experts of the respective department. The said injection was developed within the span of 5 years time. The permission was sought from federal ministry for health and regulation for laboratory test of these injections. This application was kept unattended in Islamabad secretariat, for two years. These 100000 injections which were prepared for poor patients were wasted, for want of permission by the then minister of health Ejaz Jakhrani and secretary health Khushnood Lashari.

Read more…

Share This Page
Facebooktwittergoogle_plusredditpinterestlinkedintumblrmail
Follow Us
Facebooktwitter
Tagged lack of treatment, Pakistan, Policy

Pakistan: Thousands of Pakistan made anti Hepatitis C injections expire

Hepatitis C Blog Posted on March 31, 2015 by HCV AdvocateDecember 1, 2015

Islamabad- About 10000 injections developed by Punjab University (PU)
for treatment of Hepatitis-C have gone redundant, due to negligence of
provincial and federal governments.

The government has shifted
all the burden of this scam to the shoulders of former PPP led
government. PU medical experts had developed 100000 injections for cure
of Hepatitis-C at the cost of Rs 7 million, but these have gone time
barred while lying in stores, due to non-granting of permission
by ministry of health and regulation for conducting laboratory test.

PU Molecular Biology department worked out plan to develop cheap
Interferon injection for treatment of Hepatitis C and funds were also
provided to the experts of the respective department. The said injection
was developed within the span of 5 years time. The permission was
sought from federal ministry for health and regulation for laboratory
test of these injections. This application was kept unattended in
Islamabad secretariat, for two years. These 100000 injections which were
prepared for poor patients were wasted, for want of permission by the
then minister of health Ejaz Jakhrani and secretary health Khushnood
Lashari.

Read more…

Share This Page
Facebooktwittergoogle_plusredditpinterestlinkedintumblrmail
Follow Us
Facebooktwitter
Tagged lack of treatment, Pakistan, Policy

Tazo tea luminary Steven Smith died of liver cancer caused by hepatitis C, a hidden epidemic

Hepatitis C Blog Posted on March 31, 2015 by HCV AdvocateDecember 13, 2015

After Tazo co-founder Steven Smith died at 65 on March 23, an article on his exceptional life as a serial entrepreneur and whimsical tea visionary attracted more than 100,000 clicks on oregonlive.com — a lot for a news obituary.

But some readers wrote to The Oregonian with questions. They wanted to know the cause of death. They asked why Smith, still bubbling with energy and ideas, died so relatively young.

On Monday, Smith’s widow, Kim DeMent — a remarkable woman in her own right, who runs Steven Smith Teamaker, dances with BodyVox and writes lyrically — explained why. The answer should concern baby boomers and others, because it involves a little-known epidemic that could take many more lives at any age without simple precautions.

Smith died from complications of liver cancer.

Read more…

Share This Page
Facebooktwittergoogle_plusredditpinterestlinkedintumblrmail
Follow Us
Facebooktwitter
Tagged obit, Steven Smith, Tazo

Tazo tea luminary Steven Smith died of liver cancer caused by hepatitis C, a hidden epidemic

Hepatitis C Blog Posted on March 31, 2015 by HCV AdvocateDecember 1, 2015

After Tazo co-founder Steven Smith died at 65 on March 23, an article on his exceptional life
as a serial entrepreneur and whimsical tea visionary attracted more
than 100,000 clicks on oregonlive.com — a lot for a news obituary.

But some readers wrote to The Oregonian with questions. They wanted
to know the cause of death. They asked why Smith, still bubbling with
energy and ideas, died so relatively young.

On Monday, Smith’s widow, Kim DeMent — a remarkable woman in her own right, who runs Steven Smith Teamaker, dances with BodyVox and writes lyrically — explained why. The answer should concern baby boomers and others, because it involves a little-known epidemic that could take many more lives at any age without simple precautions.

Smith died from complications of liver cancer.

Read more…

Share This Page
Facebooktwittergoogle_plusredditpinterestlinkedintumblrmail
Follow Us
Facebooktwitter
Tagged obit, Steven Smith, Tazo

Canada: Ontario decision to cover costly hepatitis C drug a lifesaver, doctor says

Hepatitis C Blog Posted on March 31, 2015 by HCV AdvocateDecember 13, 2015

Ottawa liver specialist Dr. Curtis Cooper is calling Ontario’s decision to pay for new treatments that can cure hepatitis C a “landmark event” that will change the lives of thousands of people with the disease.

Cooper, director of The Ottawa Hospital and Regional Hepatitis Program, sees thousands of hepatitis C patients, many of whom will benefit from the new drug therapy now that it is covered by the province.

“This is going to mean the difference between health or illness and death,” for many patients, he said.

Read more…

Share This Page
Facebooktwittergoogle_plusredditpinterestlinkedintumblrmail
Follow Us
Facebooktwitter
Tagged access to new drugs, Canada, Ontario, Pharmacare

Canada: Ontario decision to cover costly hepatitis C drug a lifesaver, doctor says

Hepatitis C Blog Posted on March 31, 2015 by HCV AdvocateDecember 1, 2015

Ottawa liver specialist Dr. Curtis Cooper is calling Ontario’s
decision to pay for new treatments that can cure hepatitis C a “landmark
event” that will change the lives of thousands of people with the
disease.

Cooper, director of The Ottawa Hospital and Regional Hepatitis
Program, sees thousands of hepatitis C patients, many of whom will
benefit from the new drug therapy now that it is covered by the
province.

“This is going to mean the difference between health or illness and death,” for many patients, he said.

Read more…

Share This Page
Facebooktwittergoogle_plusredditpinterestlinkedintumblrmail
Follow Us
Facebooktwitter
Tagged access to new drugs, Canada, Ontario, Pharmacare

Ireland: UP to 80 seriously ill Hepatitis C patients have cleared virus from their blood

Hepatitis C Blog Posted on March 31, 2015 by HCV AdvocateDecember 13, 2015
New treatment was given to the patients after doctors warned they were not responding to other drugs.

The treatment, which costs around €45,000 to €55,000 per patient was given to the patients after doctors warned they were not responding to other drugs.

Dr Suzanne Norris, a gastroenterologist at St James’s Hospital in Dublin, said the patients will continue to be monitored over the coming months to determine their response.

Earlier this year Health Minister Leo Varadkar said a programme was being put in place to provide early access to the powerful new direct-acting anti-viral drugs for Hepatitis C patients with the greatest clinical need, due to the advanced nature of their condition.

Read more…

Share This Page
Facebooktwittergoogle_plusredditpinterestlinkedintumblrmail
Follow Us
Facebooktwitter
Tagged access to new drugs, Ireland

Ireland: UP to 80 seriously ill Hepatitis C patients have cleared virus from their blood

Hepatitis C Blog Posted on March 31, 2015 by HCV AdvocateDecember 1, 2015
New treatment was given to the patients after doctors warned they were not responding to other drugs.

The treatment, which costs around €45,000 to €55,000 per patient was
given to the patients after doctors warned they were not responding to
other drugs.

Dr Suzanne Norris, a gastroenterologist at St James’s
Hospital in Dublin, said the patients will continue to be monitored
over the coming months to determine their response.

Earlier this
year Health Minister Leo Varadkar said a programme was being put in
place to provide early access to the powerful new direct-acting
anti-viral drugs for Hepatitis C patients with the greatest clinical
need, due to the advanced nature of their condition.

Read more…

Share This Page
Facebooktwittergoogle_plusredditpinterestlinkedintumblrmail
Follow Us
Facebooktwitter
Tagged access to new drugs, Ireland

Post navigation

← Older posts

Search This Blog

Our Blog Gets Recognized – Three Years in a Row!

The Best Hepatitis C Blogs
The Best Hepatitis C Blogs
The 6 Best Hepatitis C Blogs

Subscribe to our mailing list to receive our posts via email

* indicates required

Share This Site

Facebooktwittergoogle_plusredditpinterestlinkedintumblrmail

Follow HCV Advocate

Facebooktwitter

RSS HCV Advocate Clinical Trials Reference Guide

  • A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection (DORA)
    A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection (DORA) An open-label study to assess the pharmacokinetics (PK), safety, and efficacy of glecaprevir (GLE)/pibrentasvir (PIB) (Mavyret) in pediatric (children) participants … Continue reading → The post A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy […]
  • Evaluation of Wirelessly Observed Therapy to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Non-adherence to Treatment: Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence (DASH)
    This study will enroll subjects who are at high risk for nonadherence (including active alcohol and/drug use, recent hospitalization for a psychiatric condition, previous nonadherence or missed clinic visits, or transportation issues). This study is evaluating the use of a … Continue reading → The post Evaluation of Wirelessly Observed Therapy to Optimize Adherence in […]

Archives

  • April 2018 (44)
  • March 2018 (55)
  • February 2018 (48)
  • January 2018 (40)
  • December 2017 (28)
  • November 2017 (47)
  • October 2017 (67)
  • September 2017 (63)
  • August 2017 (54)
  • July 2017 (63)
  • June 2017 (57)
  • May 2017 (65)
  • April 2017 (82)
  • March 2017 (55)
  • February 2017 (74)
  • January 2017 (71)
  • December 2016 (76)
  • November 2016 (84)
  • October 2016 (61)
  • September 2016 (66)
  • August 2016 (79)
  • July 2016 (62)
  • June 2016 (56)
  • May 2016 (72)
  • April 2016 (61)
  • March 2016 (55)
  • February 2016 (38)
  • January 2016 (40)
  • December 2015 (48)
  • November 2015 (55)
  • October 2015 (112)
  • September 2015 (105)
  • August 2015 (101)
  • July 2015 (108)
  • June 2015 (97)
  • May 2015 (172)
  • April 2015 (139)
  • March 2015 (218)
  • February 2015 (201)
  • January 2015 (217)
  • December 2014 (93)
  • November 2014 (88)
  • October 2014 (107)
  • September 2014 (84)
  • August 2014 (65)
  • July 2014 (84)
  • June 2014 (71)
  • May 2014 (100)
  • April 2014 (95)
  • March 2014 (89)
  • February 2014 (58)
  • January 2014 (48)
  • December 2013 (60)
  • November 2013 (76)
  • October 2013 (93)
  • September 2013 (77)
  • August 2013 (75)
  • July 2013 (88)
  • June 2013 (77)
  • May 2013 (74)
  • April 2013 (69)
  • March 2013 (66)
  • February 2013 (43)
  • January 2013 (60)
  • December 2012 (40)
  • November 2012 (87)
  • October 2012 (54)
  • September 2012 (61)
  • August 2012 (68)
  • July 2012 (75)
  • June 2012 (58)
  • May 2012 (92)
  • April 2012 (89)
  • March 2012 (60)
  • February 2012 (46)
  • January 2012 (60)
  • December 2011 (54)
  • November 2011 (77)
  • October 2011 (53)
  • September 2011 (49)
  • August 2011 (35)
  • July 2011 (50)
  • June 2011 (33)
  • May 2011 (31)
  • April 2011 (34)
  • March 2011 (33)
  • February 2011 (23)
  • January 2011 (22)
  • December 2010 (18)
  • November 2010 (25)
  • October 2010 (20)
  • September 2010 (7)
  • August 2010 (5)
  • July 2010 (4)
© 2015 HCVAdvocate.org Top of Blog   
↑